CoChat

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal

Open access
Haemmerle, Monika, Bottsford-Miller, Justin, Pradeep, Sunila, Taylor, Morgan L., Choi, Hyun-Jin, Hansen, Jean M., Dalton, Heather J., Stone, Rebecca L., Cho, Min Soon, Nick, Alpa M., Nagaraja, Archana S., Gutschner, Tony, Gharpure, Kshipra M., Mangala, Lingegowda S., Rupaimoole, Rajesha, Han, Hee Dong, Zand, Behrouz, Armaiz-Pena, Guillermo N., Wu, Sherry Y., Pecot, Chad V., Burns, Alan R., Lopez-Berestein, Gabriel, Afshar-Kharghan, Vahid, Sood, Anil K. · 2016 · Journal of Clinical Investigation
Cited by 134

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Recent studies in patients with ovarian cancer suggest that tumor growth may be accelerated following cessation of antiangiogenesis therapy; however, the underlying mechanisms are not well understood. In this study, we aimed to compare the effects of therapy withdrawal to those of continuous treatment with various antiangiogenic agents. Cessation of therapy with pazopanib, bevacizumab, and the human and murine anti-VEGF antibody B20 was associated with substantial tumor growth in mouse models of ovarian cancer. Increased tumor growth was accompanied by tumor hypoxia, increased tumor angiogenesis, and vascular leakage. Moreover, we found hypoxia-induced ADP production and platelet infiltration into tumors after withdrawal of antiangiogenic therapy, and lowering platelet counts markedly inhibited tumor rebound after withdrawal of antiangiogenic therapy. Focal adhesion kinase (FAK) in platelets regulated their migration into the tumor microenvironment, and FAK-deficient platelets completely prevented the rebound tumor growth. Additionally, combined therapy with a FAK inhibitor and the antiangiogenic agents pazopanib and bevacizumab reduced tumor growth and inhibited negative effects following withdrawal of antiangiogenic therapy. In summary, these results suggest that FAK may be a unique target in situations in which antiangiogenic agents are withdrawn, and dual targeting of FAK and VEGF could have therapeutic implications for ovarian cancer management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci85086

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 134

Metadata

Authors
Haemmerle, M., Bottsford-Miller, J., Pradeep, S., Taylor, M. L., Choi, H.-J., Hansen, J. M., Dalton, H. J., Stone, R. L., Cho, M. S., Nick, A. M., Nagaraja, A. S., Gutschner, T., Gharpure, K. M., Mangala, L. S., Rupaimoole, R., Han, H. D., Zand, B., Armaiz-Pena, G. N., Wu, S. Y., Pecot, C. V., Burns, A. R., Lopez-Berestein, G., Afshar-Kharghan, V., & Sood, A. K.
Venue
Journal of Clinical Investigation
Published
2016-04-11
Volume
126
Issue
5
Pages
1885-1896
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2329307756
Cited by
134
References
6
FWCI
6.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.